Valneva (NASDAQ:VALN) Shares Gap Up – What’s Next?

Valneva SE Sponsored ADR (NASDAQ:VALN) shares gapped up prior to trading on Monday. The stock had previously closed at $5.51, but opened at $5.83. Valneva shares last traded at $5.7840, with a volume of 1,942 shares traded.

Analysts Set New Price Targets

A number of brokerages recently commented on VALN. Weiss Ratings upgraded shares of Valneva from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday. TD Cowen assumed coverage on shares of Valneva in a report on Tuesday, August 11th. They issued a “buy” rating and a $12.00 price objective for the company. One research analyst has rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Valneva has an average rating of “Reduce” and an average price target of $9.30.

Valneva Price Performance

The firm has a market capitalization of $558.77 million, a P/E ratio of -2.78 and a beta of 1.37. The company has a debt-to-equity ratio of 2.04, a quick ratio of 1.69 and a current ratio of 2.16. The business has a 50 day simple moving average of $6.04 and a two-hundred day simple moving average of $6.71.

Valneva (NASDAQ:VALN) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.21). Valneva had a negative net margin of 110.33% and a negative return on equity of 153.20%. The business had revenue of $39.37 million for the quarter, compared to the consensus estimate of $44.17 million. On average, sell-side analysts expect that Valneva SE Sponsored ADR will post -1.27 EPS for the current fiscal year.

Valneva Company Profile

Valneva is a specialty vaccine company focused on developing, manufacturing and commercializing vaccines for infectious diseases. Founded in 2013 through the combination of Vivalis and Intercell, the company is headquartered in Saint-Herblain, France, and serves markets in Europe, North America and other regions through direct operations and commercial partners. Its marketed vaccines include IXIARO, for prevention of Japanese encephalitis, and DUKORAL, an oral vaccine for cholera. Valneva also developed IXCHIQ, a vaccine to prevent disease caused by chikungunya virus, which has received regulatory authorization in the United States and Europe.